400 related articles for article (PubMed ID: 26881556)
1. A rare case: Hallucination associated with pazopanib.
Demirci NS; Erdem GU; Dogan M; Ozdemir NY; Zengin N
J Cancer Res Ther; 2015; 11(4):961-2. PubMed ID: 26881556
[TBL] [Abstract][Full Text] [Related]
2. Guillain-Barré syndrome in a patient with renal cell carcinoma following the first course of pazopanib therapy.
Koshikawa H; Tsukie T; Kurita A; Fujikura M; Suzuki M; Araki K
J Infect Chemother; 2017 Nov; 23(11):798-799. PubMed ID: 28506529
[TBL] [Abstract][Full Text] [Related]
3. An open-label extension study to evaluate safety and efficacy of pazopanib in patients with advanced renal cell carcinoma.
Sternberg CN; Davis ID; Deen KC; Sigal E; Hawkins RE
Oncology; 2014; 87(6):342-50. PubMed ID: 25227656
[TBL] [Abstract][Full Text] [Related]
4. Pazopanib outscores sunitinib on tolerability.
Cancer Discov; 2014 Jan; 4(1):OF8. PubMed ID: 24402960
[TBL] [Abstract][Full Text] [Related]
5. [First Hungarian experience with pazopanib therapy for patients with metastatic renal cancer].
Maráz A; Bodrogi I; Csejtei A; Dank M; Géczi L; Küronya Z; Mangel L; Petrányi A; Szûcs M; Bodoky G
Magy Onkol; 2013 Sep; 57(3):173-6. PubMed ID: 24107823
[TBL] [Abstract][Full Text] [Related]
6. Pazopanib-associated interstitial lung disease in a patient with renal cell carcinoma.
Harada Y; Kakimoto S; Shimizu T
BMJ Case Rep; 2020 Jul; 13(7):. PubMed ID: 32641305
[TBL] [Abstract][Full Text] [Related]
7. [Pazopanib for treatment of renal cell carcinoma and soft tissue sarcomas].
Brotelle T; Bay JO
Bull Cancer; 2014 Jun; 101(6):641-6. PubMed ID: 24977453
[TBL] [Abstract][Full Text] [Related]
8. Benefits of pazopanib over sunitinib for renal cell carcinoma.
Granovetter M
Lancet Oncol; 2016 Mar; 17(3):e93. PubMed ID: 26853821
[No Abstract] [Full Text] [Related]
9. Pembrolizumab- and/or pazopanib-induced remitting seronegative symmetrical synovitis with pitting edema in a patient with renal cell carcinoma.
Bas O; Ozbek A; Guven D; Aktepe O; Kılıc L; Kertmen N; Erman M
J Oncol Pharm Pract; 2020 Jul; 26(5):1230-1233. PubMed ID: 31735133
[TBL] [Abstract][Full Text] [Related]
10. Case of severe ulceration induced by pazopanib.
Goto H; Niwakawa M; Yoshikawa S; Otsuka M; Omodaka T; Yoshimi K; Kiyohara Y
J Dermatol; 2017 Apr; 44(4):474-476. PubMed ID: 27238880
[No Abstract] [Full Text] [Related]
11. Is change in blood pressure a biomarker of pazopanib and sunitinib efficacy in advanced/metastatic renal cell carcinoma?
Goldstein D; Rosenberg JE; Figlin RA; Townsend RR; McCann L; Carpenter C; Pandite L
Eur J Cancer; 2016 Jan; 53():96-104. PubMed ID: 26702763
[TBL] [Abstract][Full Text] [Related]
12. A randomised, double-blind phase III study of pazopanib in patients with advanced and/or metastatic renal cell carcinoma: final overall survival results and safety update.
Sternberg CN; Hawkins RE; Wagstaff J; Salman P; Mardiak J; Barrios CH; Zarba JJ; Gladkov OA; Lee E; Szczylik C; McCann L; Rubin SD; Chen M; Davis ID
Eur J Cancer; 2013 Apr; 49(6):1287-96. PubMed ID: 23321547
[TBL] [Abstract][Full Text] [Related]
13. [Atrial flutter probably related to pazopanib: A case report].
Puebla Villaescusa A; Díaz Gómez E; Salcedo Mingoarranz ÁL; Ramírez Cruz S; Hidalgo Correas FJ; García Díaz B
Farm Hosp; 2018 Jan; 42(1):33-34. PubMed ID: 29306315
[No Abstract] [Full Text] [Related]
14. Phase II study of pazopanib as second-line treatment after sunitinib in patients with metastatic renal cell carcinoma: a Southern China Urology Cancer Consortium Trial.
Xie M; He CS; Huang JK; Lin QZ
Eur J Cancer; 2015 Mar; 51(5):595-603. PubMed ID: 25618828
[TBL] [Abstract][Full Text] [Related]
15. Pazopanib for the treatment of metastatic renal cell carcinoma.
Pick AM; Nystrom KK
Clin Ther; 2012 Mar; 34(3):511-20. PubMed ID: 22341567
[TBL] [Abstract][Full Text] [Related]
16. Pazopanib-Associated Drug Reaction With Eosinophilia and Systemic Symptoms Syndrome: A Case Report.
Singh P; DʼAngelo RN; Huang V
Am J Ther; 2019; 26(5):e636-e638. PubMed ID: 30946042
[No Abstract] [Full Text] [Related]
17. Safety and tolerability of pazopanib in the treatment of renal cell carcinoma.
Zivi A; Cerbone L; Recine F; Sternberg CN
Expert Opin Drug Saf; 2012 Sep; 11(5):851-9. PubMed ID: 22861374
[TBL] [Abstract][Full Text] [Related]
18. Pazopanib- and bevacizumab-induced reversible heart failure in a patient with metastatic renal cell carcinoma: A case report.
Abdallah AO; Vallurupalli S; Kunthur A
J Oncol Pharm Pract; 2016 Jun; 22(3):561-5. PubMed ID: 25956420
[No Abstract] [Full Text] [Related]
19. Pazopanib as second-line treatment after sunitinib or bevacizumab in patients with advanced renal cell carcinoma: a Sarah Cannon Oncology Research Consortium Phase II Trial.
Hainsworth JD; Rubin MS; Arrowsmith ER; Khatcheressian J; Crane EJ; Franco LA
Clin Genitourin Cancer; 2013 Sep; 11(3):270-5. PubMed ID: 23665131
[TBL] [Abstract][Full Text] [Related]
20. Reversible posterior leukoencephalopathy syndrome induced by pazopanib.
Chelis L; Souftas V; Amarantidis K; Xenidis N; Chamalidou E; Dimopoulos P; Michailidis P; Christakidis E; Prassopoulos P; Kakolyris S
BMC Cancer; 2012 Oct; 12():489. PubMed ID: 23088634
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
